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Letter to the Editor
A therapeutic dilemma between 
the two “R”s: additional rituximab 
or radiotherapy for limited, non- 
bulky diffuse large B-cell lym-
phoma
TO THE EDITOR: Limited disease, defined as Ann Arbor 
stage I and non-bulky stage II, accounts for approximately 
25% of diffuse large B-cell lymphomas (DLBCLs). Since 
the Southwest Oncology Group (SWOG) study 8736 demon-
strated that 3 cycles of cyclophosphamide, doxorubicin, vin-
cristine, and prednisone (CHOP) followed by involved-field 
radiotherapy (IFRT) was superior to 8 cycles of CHOP [1], 
a short course of chemotherapy followed by IFRT has been 
the main treatment for limited, non-bulky DLBCL. This 
treatment strategy has not changed even after the efficacy 
of rituximab-CHOP (R-CHOP) was proved in the Groupe 
d’Etude des Lymphomes de l’Adulte (GELA) study of ad-
vanced-stage DLBCL [2]. Hence, the current National 
Comprehensive Cancer Network (NCCN) Clinical Practice 
Guidelines (Version I. 2011) recommend 2 treatment options 
for stage I/II, non-bulky DLBCL: 3 cycles of R-CHOP with 
subsequent IFRT and 6 cycles of R-CHOP with or without 
IFRT. However, the role of radiotherapy for controlling 
localized DLBCL has been debatable because radiotherapy- 
associated toxicity may deteriorate the quality of life as 
well as survival outcome, and in many patients, the disease 
may relapse outside the radiation field [1, 3]. There is also 
the risk of secondary malignancies caused by exposure to 
the radiation field [1, 3]. This controversial use of radio-
therapy for consolidation has been augmented by the result 
of a GELA trial (LNH 93-4) that compared 4 cycles of CHOP 
with or without IFRT for patients older than 60 years with 
limited DLBCL and showed similar outcomes [3]. 
  The need for radiotherapy has been challenged since 
R-CHOP was used as standard treatment for patients with 
DLBCL. No study has compared the effect of a short course 
of R-CHOP plus radiotherapy with extended cycles of 
R-CHOP alone for limited DLBCL; hence, physicians can 
choose to perform IFRT or 3 additional cycles of R-CHOP 
at their discretion. Because the selection of a treatment 
modality for consolidation after 3 cycles of R-CHOP is debat-
able, 3 additional cycles of R-CHOP or IFRT are suggested 
as a therapeutic option in the NCCN guidelines. 
  In the previous issue, Hong et al. reported the results 
of comparing 3-4 cycles of R-CHOP plus IFRT with 6-8 
cycles of R-CHOP alone in limited, non-bulky DLBCL [4]. 
The 2 groups that were compared showed similar 3-year 
overall survival (OS). Their OS was comparable to that ob-
served in a previous study (SWOG 0014) that tested the 
utility of adding 4 doses of rituximab to 3 cycles of CHOP 
with subsequent IFRT [5]. However, the study by Hong 
et al. involved a retrospective analysis with a small number 
of patients. Their results do not provide information helpful 
in selecting a treatment strategy. Furthermore, extended 
cycles of R-CHOP might increase the risk of febrile neu-
tropenia, as evidenced by 1 treatment-related mortality that 
occurred in the group that underwent 6-8 cycles of R-CHOP 
[4]. Therefore, the selection of additional R-CHOP or IFRT 
as a consolidation for limited, non-bulky DLBCL will remain 
a therapeutic dilemma until a prospective study involving 
a large study population is conducted.
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